elcuidadodelasalude.org



Research and Markets releases textbook for neurological practice

November 12, 2015

"With these latest findings we continue to extend our understanding of the genetic risk factors for prostate cancer, the second most common cause of cancer deaths in men. Using our ability to put these SNPs in a population-wide context, we show that it is now possible to identify those who are at more than 30% lifetime risk, independent of other standard risk factors such as age and family history. By incorporating this new, personalized gauge of susceptibility into our arsenal for improving prevention and early diagnosis, we can more effectively and accurately identify those men who would benefit most from intensive screening. We are pleased to be incorporating these latest markers into our deCODE ProstateCancer(TM) test," said Kari Stefansson, CEO of deCODE.

Today's findings result from the analysis of several large datasets: deCODE's genome-wide SNP data from tens of thousands of patients and healthy controls from Iceland; sequencing data from regions in the genome where deCODE and others have already discovered prostate cancer risk factors; and publicly available data from other case-control cohorts from the US, France and Finland. Data from a combined total of more than 60,000 patients and healthy control subjects were included in the study.

The paper, 'Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility,' is published today in the online edition of Nature Genetics, at nature/ng.

decode/